Stock Market & Financial Investment News

News Breaks September 13, 2012 07:35 EDT BIIB, SNY Biogen to benefit from easy Aubagio approval, says RBC Capital After Sanofi's (SNY) Aubagio was approved on time and without a panel, RBC Capital believes that this development decreases the likelihood that Biogen's BG-12 will face any regulatory difficulties. The firm thinks the outlook for Biogen's ALS treatment is more risky, but recommends buying Biogen on any pullback related to negative data for that drug. The firm maintains an Outperform rating on the stock. News For BIIB;SNY From The Last 14 Days Check below for free stories on BIIB;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 07:44 EDT SNY Sachs Associates to host a forum Subscribe for More Information 07:24 EDT BIIB Global Health Care to host a conference Subscribe for More Information 05:44 EDT BIIB Biogen submits application to FDA for approval of Plegridy in RMS Subscribe for More Information May 20, 2013 17:26 EDT SNY Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information 15:57 EDT BIIB Biogen IMS numbers should not be adjusted down at ISI Group ISI Group confirmed with Biogen that Tecfidera is not captured by IMS and numbers should not be adjusted downward to reflect free drugs dispensed. 11:27 EDT SNY Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva Subscribe for More Information 07:39 EDT BIIB Biogen weekly MS drug scripts up 26.5%, says Citigroup Citigroup says weekly scripts for Biogen's multiple sclerosis drug Tecfidera were up 26.5% to 1,621. Citi says the launch of Tecfidera is on track to beat Q2 estimates by a wide margin and it keeps a Buy rating on shares of Biogen. May 17, 2013 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 16, 2013 07:29 EDT BIIB Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. May 15, 2013 15:16 EDT SNY Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information 05:39 EDT SNY Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information May 14, 2013 15:09 EDT BIIB Biogen has a conference call hosted by JPMorgan JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. May 13, 2013 11:12 EDT BIIB Biogen MS drug scripts grew 38% week-over-week, says Leerink Subscribe for More Information 09:44 EDT SNY Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:34 EDT BIIB Biogen says FDA accepts BLA for Eloctate Subscribe for More Information 07:30 EDT SNY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. May 10, 2013 11:48 EDT SNY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 08:00 EDT BIIB Biogen should be bought on weakness before Q2 Tecfidera data, says Stifel Stifel recommends buying Biogen on any weakness before the company reports Q2 Tecfidera sales data. The firm thinks that any continued strength in Tecfidera prescription data will cause analysts to revise their estimates higher, and it keeps a Buy rating on the shares. May 9, 2013 16:59 EDT BIIB Isis Pharmaceuticals earns $3.5M from Biogen Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.